Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: A randomized trial

AIDS

Volumn 24, Issue 1, 2010, Pages 77-83

  Aslangul, Elisabeth ^a,b   Assoumou, Lambert ^c,d   Bittar, Randa ^e,f   Valantin, Marc Antoine ^c,d,g   Kalmykova, Olga ^c,d   Peytavin, Gilles ^h   Fiévet, Marie Hélène ^g   Boccara, Franck ⁱ   Bonnefont Rousselot, Dominique ^e,f   Melchior, Jean Claude ^j   Giral, Philippe ^g   Costagliola, Dominique ^c,d,g  

^a LIPADE   (France)

^b HÔTEL DIEU   (France)

^c INSERM   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e Groupe Hospitalier Avicenne Jean Verdier Rene Muret   (France)

^f FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h BICHAT HOSPITAL   (France)

ⁱ ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^j RAYMOND POINCARÉ HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; FOSAMPRENAVIR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOPINAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; RITONAVIR; ROSUVASTATIN; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL; ZIDOVUDINE;

ADULT; ARTICLE; CATARACT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DYSLIPIDEMIA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; TUBERCULOSIS; URINARY TRACT INFECTION;

ADULT; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DYSLIPIDEMIAS; FEMALE; FLUOROBENZENES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; PRAVASTATIN; PYRIMIDINES; SULFONAMIDES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 73649145863     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328331d2ab     Document Type: Article

References (21)

1. Calza L, Manfredi R, Chiodo F. Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART. Infection 2002; 30:26-31.
2. Gerber JG, Kitch DW, Fichtenbaum CJ, Zackin RA, Charles S, Hogg E, et al. Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J Acquir Immune Defic Syndr 2008; 47:459-466.
3. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 2001; 120:525-533.
4. Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 2004; 76:167-177.
5. Bonnet F, Balestre E, Thiebaut R, Mercie P, Dupon M, Morlat P, et al. Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999-2001. HIV Med 2004; 5:133-139.
6. Carswell CI, Plosker GL, Jarvis B. Rosuvastatin. Drugs 2002; 62:2075-2085; discussion 86-87
7. Moyle GJ, Buss NE, Gazzard BG. Pravastatin does not alter protease inhibitor exposure or virologic efficacy during a 24-week period of therapy. J Acquir Immune Defic Syndr 2002; 30:460-462.
8. Fichtenbaum CJ, Gerber JG. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmaco-kinet 2002; 41:1195-1211.
9. Fossati P, Prencipe L. Serum triglycerides determined color-imetrically with an enzyme that produces hydrogen peroxide. Clin Chem 1982; 28:2077-2080.
10. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem 1974; 20:470-475.
11. Egloff M, Leglise D, Duvillard L, Steinmetz J, Boyer MJ, Ruelland A, et al. Multicenter evaluation on different analyzers of three methods for direct HDL-cholesterol assay. Ann Biol Clin (Paris) 1999; 57:561-572.
12. Bayer P, Veinberg F, Couderc R, Cherfils C, Cambillau M, Cosson C, et al. Multicenter evaluation of four homogenous LDL-cholesterol assays. Ann Biol Clin (Paris) 2005; 63:27-41.
13. Katlama C, Dominguez S, Gourlain K, Duvivier C, Delaugerre C, Legrand M, et al. Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097). AIDS 2004; 18:217-226.
14. Otter K, Mignat C. Determination of pravastatin in human plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl 1998; 708:235-241.
15. Hull CK, Penman AD, Smith CK, Martin PD. Quantification of rosuvastatin in human plasma by automated solid-phase extraction using tandem mass spectrometric detection. J Chro-matogr B Analyt Technol Biomed Life Sci 2002; 772:219-228.
16. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLARM Trial). Am J Cardiol 2003; 92:152-160.
17. Calza L, Colangeli V, Manfredi R, Legnani G, Tampellini L, Pocaterra D, Chiodo F, et al. Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study. AIDS 2005; 19:1103-1105.
18. van der Lee M, Sankatsing R, Schippers E, Vogel M, Fatkenheuer G, van der Ven A, et al. Pharmacokinetics and pharmacody-namics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. Antivir Ther 2007; 12:1127-1132.
19. Calza L, Manfredi R, Colangeli V, Pocaterra D, Pavoni M, Chiodo F. Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors. Curr HIV Res 2008; 6:572-578.
20. Stender S, Schuster H, Barter P, Watkins C, Kallend D. Comparison of rosuvastatin with atorvastatin, simvastatin and pra-vastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial. Diabetes Obes Metab 2005; 7:430-438.
21. McTaggart F, Buckett L, Davidson R, et al. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001; 87 (5A):28B-32B.